CNBC's Meg Tirrell reports on Gilead's new drug that cures Hepatitis C.
Feb 9- Drugstore chain and pharmacy benefits manager CVS Health Corp reported an 11.7 percent rise in quarterly revenue on Thursday, helped by strength in its PBM business. Net income attributable to CVS rose to $1.71 billion, or $1.59 per share, in the fourth quarter ended Dec. 31, from about $1.50 billion, or $1.34 per share, a year earlier. Revenue rose to $45.97...
The new terms set shares of Rite Aid at a maximum of $7 per share and $6.50 minimum, down from the initial $9 Walgreens agreed to purchase.
Novo Nordisk is investing 115 million pounds in a new research center in Britain, undeterred by Brexit.
Shares of Walgreen Boots Alliance and Rite Aid are trading lower after the merger of the two drugstore companies is facing US antitrust concerns.
"Fast Money" trader David Seaburg pitches to the desk why to buy Eli Lilly.
Michael King, JMP Securities senior analyst, weighs in on the biotech sector as President-elect Donald Trump puts the pharmaceutical industry in his cross hairs, calling it "disastrous."
CNBC's Bob Pisani and Art Cashin, of UBS, discuss the market’s reaction to President-elect Donald Trump’s first news conference since Election Day.
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing under President-elect Donald Trump as he pushes to bring drug prices down.
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing.
CNBC's Meg Tirrell speaks with Express Scripts President & CEO Tim Wentworth on pharmacy benefit managers and drug pricing pressure.
Valeant CEO Joseph Papa speaks to CNBC's Meg Tirrell about the company's turnaround process and drug price increases.
Johnson & Johnson CEO Alex Gorsky speaks to CNBC's Meg Tirrell about his company's expectations for 2017, Donald Trump's impact on the drug industry and potential M&A plans.
A judge ruling blocks Sanofi and partner Regeneron from selling their cholesterol drug, which is a victory for Amgen. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell reports on how first responders deal with emergency opioid overdose calls, and potential headwinds.
CNBC's Meg Tirrell reports on how high drug prices are limiting access to life-saving drugs such as Naloxone.
CNBC's Meg Tirrell reports the latest on the war on drug prices as several drugs are seeing their prices hiked since the start of the year.
CNBC's Meg Tirrell reports that one analyst is raising a red flag on Biogen due to the incredibly high price of a new drug to treat a rare genetic disease in children.
So-called "superbugs" "threaten the achievements of modern medicine," according to the World Health Organization.
CNBC's Meg Tirrell reports on what Donald Trump's push to lower drug prices may mean for the pharmaceutical industry.